MedWatch alert for Tysabri
Executive Summary
Biogen Idec and Elan are issuing a "Dear Healthcare Professional" letter alerting physicians about a risk of hepatotoxicity with Tysabri use. FDA updated the Warnings section of natalizumab labeling in January to include reports of significant liver injury. The multiple sclerosis treatment, which recently was approved for Crohn's disease, has an extensive risk management plan in place limiting prescriptions and distribution to healthcare practitioners registered with the TOUCH program (1"The Pink Sheet," Jan. 21, 2008, p. 9)
You may also be interested in...
Tysabri For Crohn’s: Risk Management Is Same, But Could Be Higher Hurdle
The approval of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) for Crohn's disease will expand the use of the product's multi-layered risk management program
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.